Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Last trade$8.07
Day change-$0.04 (-0.49%)
Day range$8.02 – $8.22
Volume49,567
Market cap$468M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$468.21M
Price / earnings
—
Price / book
6.75×
Price / sales
6.19×
EV / sales
6.12×
EV / EBITDA
-144.19×
Profitability
Earnings per share
-$0.13
Return on assets
-7.63%
Return on equity
-10.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
3.55×
Quick ratio
2.24×
Cash ratio
0.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KMDA, quarterly periods
Line item
Q2 FY2016 Jun 30, 2016
Q1 FY2016 Mar 31, 2016
Q4 FY2015 Dec 31, 2015
Q3 FY2015 Sep 30, 2015
Q2 FY2015 Jun 30, 2015
Q1 FY2015 Mar 31, 2015
Q4 FY2014 Dec 31, 2014
Q3 FY2014 Sep 30, 2014
Revenue
$19.07M
$14.8M
$25.66M
$16.07M
$19.25M
$8.93M
$24.93M
$17.15M
Cost of revenue
$13.44M
$10.02M
$17.6M
$12.36M
$15.61M
$8.54M
$17.46M
$12.78M
Gross profit
$5.63M
$4.78M
$8.06M
$3.71M
$3.64M
$392K
$7.47M
$4.38M
Selling, general and administrative
$2.72M
$2.65M
$2.84M
$2.67M
$2.68M
$2.5M
$2.44M
$2.69M
Research and development
$3.5M
$4.11M
$4.43M
$5.05M
$3.42M
$3.64M
$3.42M
$4.18M
Total operating expenses
$6.22M
$6.76M
$7.27M
$7.72M
$6.1M
$6.14M
$5.86M
$6.87M
Operating income
-$590K
-$1.98M
$793K
-$4.01M
-$2.46M
-$5.75M
$1.62M
-$2.5M
Interest expense
-$30K
-$37K
-$110K
-$333K
-$248K
-$243K
-$416K
-$519K
Income before taxes
-$397K
-$2M
$988K
-$4.62M
-$2.34M
-$5.29M
$1.15M
-$2.86M
Income taxes
$1.19M
$300K
—
—
—
—
-$18K
$36K
Net income
-$1.59M
-$2.3M
$988K
-$4.62M
-$2.34M
-$5.29M
$1.17M
-$2.9M
Net income attributable to common shareholders
-$1.59M
-$2.3M
$988K
-$4.62M
-$2.34M
-$5.29M
$1.17M
-$2.9M
EBITDA
$288K
-$1.15M
$793K
-$3.15M
-$1.66M
-$4.98M
$1.62M
-$1.77M
Basic earnings per share
-$0.04
-$0.06
$0.03
-$0.13
-$0.06
-$0.15
$0.04
-$0.09
Diluted earnings per share
-$0.04
-$0.06
$0.03
-$0.13
-$0.06
-$0.15
$0.04
-$0.09
Recent news
Company coverage with links to the original publishers.
Eton Pharmaceuticals reported Q3 2026 earnings of $1.06 per share, significantly beating the consensus estimate of $0.34 per share, representing a 211.77% earnings surprise. Revenues reached $57.93 million, surpassing estimates by 37.23% compared to $22.46 million year-ago. The stock has gained 199.9% year-to-date. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.
Kamada Ltd. announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Beit Kama, Israel. The facility will enhance quality control and testing capabilities for the company's rabies immunoglobulin products KEDRAB and KAMRAB, which generated over $70 million in 2025 sales. The laboratory represents a significant expansion of Kamada's advanced testing capabilities and demonstrates the company's commitment to innovation and operational efficiency.
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced it will release its first quarter 2026 financial results on May 13, 2026, followed by a management conference call. The company operates three FDA-approved plasma collection centers in Texas and focuses on growth through its commercial portfolio of specialty plasma products, third-party pharmaceutical distribution, plasma collection operations, and strategic M&A opportunities.
Kamada Ltd. announced FDA approval of its San Antonio, Texas plasma collection center following an on-site inspection in February 2026. The 11,100 square foot facility has a planned capacity of approximately 50,000 liters per year and is expected to generate $8-10 million in annual revenues from normal source plasma sales at full capacity. The center is anticipated to be one of the largest specialty plasma collection centers in the U.S., complementing Kamada's existing operations in Houston and Beaumont, Texas.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.14 per share
Declared
Nov 9, 2026
Ex-dividend
Nov 19, 2026
Pay date
Dec 9, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 27, 2026
$0.17
Sep 17, 2026
recurring
Mar 23, 2026
$0.25
Apr 7, 2026
recurring
Mar 17, 2025
$0.20
Apr 7, 2025
special
Stock splits
Historical share-structure events and their execution dates.